1. Home
  2. ELVN vs VRTS Comparison

ELVN vs VRTS Comparison

Compare ELVN & VRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • VRTS
  • Stock Information
  • Founded
  • ELVN 2016
  • VRTS 1988
  • Country
  • ELVN United States
  • VRTS United States
  • Employees
  • ELVN N/A
  • VRTS N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • VRTS Investment Managers
  • Sector
  • ELVN Health Care
  • VRTS Finance
  • Exchange
  • ELVN Nasdaq
  • VRTS Nasdaq
  • Market Cap
  • ELVN 1.2B
  • VRTS 1.4B
  • IPO Year
  • ELVN 2020
  • VRTS 1992
  • Fundamental
  • Price
  • ELVN $19.72
  • VRTS $201.11
  • Analyst Decision
  • ELVN Strong Buy
  • VRTS Hold
  • Analyst Count
  • ELVN 5
  • VRTS 4
  • Target Price
  • ELVN $41.20
  • VRTS $188.25
  • AVG Volume (30 Days)
  • ELVN 421.4K
  • VRTS 78.9K
  • Earning Date
  • ELVN 08-13-2025
  • VRTS 10-24-2025
  • Dividend Yield
  • ELVN N/A
  • VRTS 4.51%
  • EPS Growth
  • ELVN N/A
  • VRTS 37.35
  • EPS
  • ELVN N/A
  • VRTS 20.53
  • Revenue
  • ELVN N/A
  • VRTS $888,980,000.00
  • Revenue This Year
  • ELVN N/A
  • VRTS N/A
  • Revenue Next Year
  • ELVN $25.00
  • VRTS $1.36
  • P/E Ratio
  • ELVN N/A
  • VRTS $9.72
  • Revenue Growth
  • ELVN N/A
  • VRTS 0.99
  • 52 Week Low
  • ELVN $13.30
  • VRTS $142.18
  • 52 Week High
  • ELVN $30.03
  • VRTS $252.82
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 47.40
  • VRTS 55.81
  • Support Level
  • ELVN $18.80
  • VRTS $192.70
  • Resistance Level
  • ELVN $21.30
  • VRTS $199.11
  • Average True Range (ATR)
  • ELVN 0.99
  • VRTS 5.06
  • MACD
  • ELVN -0.06
  • VRTS 0.25
  • Stochastic Oscillator
  • ELVN 36.80
  • VRTS 80.28

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

About VRTS Virtus Investment Partners Inc.

Virtus Investment Partners Inc provides investment management and related services to institutions and individuals. It uses a multi-manager, multi-style approach, offering investment strategies from investment managers, each having its distinct investment style, autonomous investment process, and individual brand, as well as from select unaffiliated managers for certain funds. Through its multi-manager model, the group provides investment managers with distribution, business, and operational support. The Company operates in one business segment, namely as an asset manager providing investment management and related services for individual and institutional clients.

Share on Social Networks: